• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OncoSec Medical

OncoSec wins CE mark for electroporation device to treat solid tumors

April 14, 2021 By Sean Whooley

Oncosec

OncoSec Medical (NSDQ:ONCS) announced today that it received CE mark approval for its next-generation device to enable better uptake of anti-cancer therapies. GenPulse, part of OncoSec’s electroporation device platform for treating solid tumors, is designed to apply short electric impulses to a tumor, according to a news release. Get the full story at our sister site, […]

Filed Under: Oncology, Regulatory/Compliance Tagged With: OncoSec Medical

OncoSec, Inovio testing COVID-19 vaccines

April 8, 2020 By Sean Whooley

OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]

Filed Under: Business/Financial News, Clinical Trials, Discovery, Featured, Food & Drug Administration (FDA), Immunotherapy, Pharmaceuticals, Preclinical Trials, Regulatory/Compliance, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, OncoSec Medical

OncoSec $30m fundraise threatened by spat

December 2, 2019 By Chris Newmarker

OncoSec

OncoSec Medical (NSDQ:ONCS) is embroiled in a lawsuit and proxy war over a $30 million money-raise as it seeks to continue development of its cancer treatment technology. The company — headquartered in San Diego and Pennington, N.J. — sent a letter to shareholders today in which it countered what it described as false and misleading statements […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Oncology Tagged With: Alpha Holdings, Cancer, China Grand Pharmaceutical and Healthcare Holdings, OncoSec Medical, Sirtex Medical Holdings

OncoSec shares fall on preliminary data from skin cancer trial

November 6, 2018 By Sarah Faulkner

OncoSec

Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma. OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response. As of Sept. 1, 21 people […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Merck, OncoSec Medical

OncoSec inks research deal to analyze clinical trial participants

August 6, 2018 By Sarah Faulkner

OncoSec

OncoSec Medical (NSDQ:ONCS) said today that it inked a research deal with Dr. Roger Lo and his research team at the University of California Los Angeles to study participants from the biotech company’s Pisces/Keynote-695 Phase IIb clinical trial. Dr. Lo and his team are slated to perform genetic, transcriptomic and methylomic analyses of patients from OncoSec’s […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: OncoSec Medical

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

May 8, 2018 By Sarah Faulkner

OncoSec

OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer. The trial is slated to study the drug-device combination in patients with inoperable locally advanced or metastatic cancer who have failed […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Merck, OncoSec Medical

OncoSec looks to boost effects of immunotherapy with intratumoral delivery

April 16, 2018 By Sarah Faulkner

OncoSec

Thousands of cancer patients have been treated with immune checkpoint inhibitors since the first of its kind was approved in 2011. The product is designed to block the production of proteins that prevent the body’s immune system from acting in the presence of cancer. Although checkpoint inhibitors hold immense promise for some patients, many fail to […]

Filed Under: Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: OncoSec Medical

OncoSec Medical prices $20m public offering

February 1, 2018 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS) today priced an underwritten public offering of 13,333,334 shares of its common stock at $1.50 apiece. The San Diego, Calif.-based company expects the offering to bring in $20 million to help fund its Phase II melanoma trial, as well as other clinical and R&D activities. As part of the offering, OncoSec gave underwriters […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: OncoSec Medical

OncoSec Medical lands $9.3m in warrant exercise deal

November 14, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS) said yesterday that it inked a warrant exercise agreement with unnamed holders of outstanding warrants to buy up to 5.5 million shares of the company’s common stock at an exercise price of $1.69 apiece. The San Diego, Calif.-based company raised $9.3 million in gross proceeds from the exercise of the warrants, which it plans […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: OncoSec Medical

OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017

November 9, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS)  announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office. O’Connor joined OncoSec’s board of directors in September this year. “We are pleased to welcome Dan to OncoSec at this important time, and believe […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Anika Therapeutics Inc., bostonbiomedical, Brainstorm Cell Therapeutics, DelMar Pharmaceuticals, Express Scripts, GlaxoSmithKline plc, OncoSec Medical, Pulmatrix Inc.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS